comparemela.com

Latest Breaking News On - Unresectable hepatocellular carcinoma hcc - Page 1 : comparemela.com

Camrelizumab With Rivoceranib Elicits PFS and OS Benefit Over Sorafenib in Unresectable HCC

Amit Mahipal, MD, discusses clinical outcomes with camrelizumab plus rivoceranib as first-line treatment in unresectable HCC, based on data from the randomized, open-label, international phase 3 CARES-310 trial.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.